Objective:

To report corrected results after excluding the retracted LungTIME-C01 trial from a systematic review and meta-analysis of time-of-day immunotherapy administration and outcomes in advanced cancers.

Approach:

• Updated dataset: The analysis was repeated without the 210 participants in LungTIME-C01, reducing the evidence base from 29 studies and 6,129 patients to 28 studies and 5,919 patients.
• Methods: The original statistical methods were retained, including primary and subgroup analyses, sensitivity analyses, and assessments of heterogeneity and publication bias.

Key Findings:

• The revised pooled hazard ratio for overall survival was 0.61 (95% CI, 0.52-0.71), compared with 0.60 (95% CI, 0.51-0.70) in the original report.
• The revised pooled hazard ratio for progression-free survival was 0.65 (95% CI, 0.57-0.74), compared with 0.62 (95% CI, 0.54-0.71) previously.

Interpretation:

The correction updated study and patient counts, pooled estimates, and related descriptions throughout the article and supplementary materials.

Conclusion:

The retracted trial was excluded, its risk-of-bias assessment was removed, and supplementary table and figure numbering was revised.